NEPHROPLUS Nephrocare Health Services Q1 FY27 results (Apr–Jun 2026) and concall
Nephrocare Health Services Limited reported a strong Q1 FY27, with revenue growing 23.7% to INR282 crores and Adjusted EBITDA increasing 30.7% to INR65 crores, driven by robust patient growth and international expansion. Margins expanded significantly, with Adjusted EBITDA margin at 23.1% and PAT margin at 13.1%. The company continued its network expansion, adding 26 new clinics, and focused on operational efficiencies and technology adoption, though Saudi Arabia remains an investment-heavy market with uncertain timelines.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 23.7%, net profit up 33.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 197 | 219 | 228 | 246 | 260 +32% | 266 +21% | 282 +24% |
| EBITDA | 44 | 51 | 48 | 64 | 61 +39% | 51 +0% | 60 +25% |
| Net profit | 20 | 25 | 24 | -9 | 32 +60% | 30 +20% | 32 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
